Analgesia aNd caNcer recUrrence Lung cAncer Resection

Impact of Analgesia on Cancer Recurrence and Mortality Within Five Years After Stage I Non-Small Cell Lung Cancer Resection

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04656769

Enrollment

382

Registered

2020-12-07

Start date

2018-12-17

Completion date

2020-11-30

Last updated

2020-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia, Opioid Use, Unspecified, Recurrence Tumor, Thoracic Surgery

Keywords

Recurrence tumor, Opioid use, Analgesia, thoracic surgery

Brief summary

The choice of analgesia after cancer surgery may play a role in the onset of recurrence, particularly opioids seem to play a role in the immune system by promoting cancer cell proliferation and migration. Based on this consideration, our aim was to assess the impact of perioperative analgesia's choice on cancer recurrence after curative surgery for Stage I Non-Small Cell Lung Cancer. The investigators retrospectively reviewed the records of patients who underwent lung resection for Stage I NSCLC between January 2005 and December 2012. Patients received analgesia either by peridural (PERI group) or, in case of patient refusal or failure in catheter positioning, intravenous analgesia with opioids (EV group). Follow-up was concluded in August 2019. The five-year cumulative incidence of recurrence and the overall survival were evaluated and adjusted with a propensity score matching methodology.

Interventions

PROCEDUREPeridural analgesia

We attempted to evaluate the effectiveness of peridural analgesia through cancer survival and recurrence outcomes.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥ 18 yrs * Patients who underwent lung resection for Stage I NSCLC between January 2005 and December 2012

Exclusion criteria

* Age\<18aa * Pregnancy * Day hospital patients

Design outcomes

Primary

Measure	Time frame
cumulative incidence of recurrence and the overall survival	5 years

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026